Clinical Trial Update: Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial of nivolumab, ixazomib, cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma was terminated with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• ixazomib (ixazomib)
• nivolumab (nivolumab)

Snippet

Sponsor: Andrew Yee, MD | Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2023-08-21